GLP1R and metabolic dysfunction-associated steatotic liver disease: Currently, there is a dearth of studies that may guide the concomitant use of GLP-1 receptor agonists and SGLT-2 inhibitors, and no existing proof regarding the use of semaglutide and empagliflozin combination in treating patients with T2DM and NAFLD [20].